Biomarker testing is revolutionizing oncology - here is Dejan Juric from Mass General Cancer Center talking about tailoring cancer treatment to the patient by way of biomarker testing. https://lnkd.in/gxKg2HcE #PrecisionMedicine #Oncology #BiomarkerTesting
SurvivorNet’s Post
More Relevant Posts
-
Discover the potential of antibody-drug conjugates in cancer treatment. Our list of the current approved ADC drugs is now available as a PDF download. Get your copy today and stay informed! 🤩📑 #ADCs #ADCPipeline #LARVOLCLIN #Oncology #CancerResearch
To view or add a comment, sign in
-
20 years of EGFR in NSCLC: how precision medicine helps navigate lung cancer challenges 💊 bit.ly/4ciaGTn Johnson & Johnson #pharma #NSCLC #EGFR #LungCancer #Oncology
To view or add a comment, sign in
-
🌍 Revolutionizing Cancer Care in Turkey! 🌍 Turkey is making groundbreaking strides in oncology, offering state-of-the-art diagnostic tools and advanced treatments like CyberKnife® and proton therapy. Patients are experiencing faster recovery times and improved outcomes. With an impressive 80% success rate, Turkey has become a global destination for affordable, cutting-edge cancer care. Curious about the future of oncology? Check out Maple Med Global’s latest blog post at maplemedglobal.ca. #Oncology #CancerTreatment #HealthCareInnovation #MapleMedGlobal
🩺 How is Turkey revolutionizing cancer care? With state-of-the-art diagnostic tools and advanced treatments like CyberKnife® and proton therapy, patients are experiencing improved outcomes and faster recovery times. In our latest article, we highlight the 80% success rate Turkey has achieved in oncology, making it a global destination for affordable and cutting-edge cancer treatments. 🌍 Learn more about the future of oncology care by reading our latest blog post at https://lnkd.in/gis5NErN. #Oncology #CancerTreatment #HealthCareInnovation #MapleMedGlobal
To view or add a comment, sign in
-
We have a Phase 2 Ready orally administered p38 MAP Kinase inhibitor, which is a potential preventative therapy targeting an addressable market that exceeds US$10 billion. POLB 001 is being developed for the prevention of Cytokine Release Syndrome (CRS) associated with cancer immunotherapy treatments, which can affect >70% of patients undergoing #CART of #BispecificAntibody therapy. Learn more about its potential, our compelling data, the major market opportunity & more here: https://lnkd.in/eFxUhvex #POLB #CRS #Oncology
To view or add a comment, sign in
-
We’re glad to share the positive data from our oncology pipeline update at today's investor meeting. Encouraged by the progress we're making in cancer treatment. https://lnkd.in/gtE7VKYu #Oncology #innoventbiologics
To view or add a comment, sign in
-
Researchers have discovered that lidocaine, a common numbing agent, might help treat head and neck cancer. Their study shows that lidocaine can activate certain receptors in cancer cells, causing them to die. This finding could lead to new treatment options for patients. The team is planning a clinical trial to test adding lidocaine to current cancer therapies. To learn more about this research, visit: - https://lnkd.in/gs9k-QF8 - https://lnkd.in/gk_gpqpQ #CancerResearch #Lidocaine #HeadAndNeckCancer #CancerTreatment #ClinicalTrials #InnovativeTherapies #HealthScience #Oncology #ResearchInProgress #theodha #RDH
To view or add a comment, sign in
-
Join us tomorrow, Sunday, June 2, during the ASCO Annual Meeting for a groundbreaking poster presentation between 9:00 a.m. to 12:00 p.m. Our recent study utilizing the ConcertAI Oncology Dataset has revealed promising results for patients with metastatic castration-resistant prostate cancer. Through a collaboration with Merck and AstraZeneca our real-world analysis has demonstrated that early treatment with Olaparib monotherapy could potentially enhance the duration of therapy and overall survival rates for these patients. This study underscores the importance of leveraging data to make informed treatment decisions that can ultimately improve patient outcomes. Read abstract: https://hubs.ly/Q02z9qws0 #ASCO24 #OncologyResearch #RealWorldData #OlaparibMonotherapy #PatientCare
To view or add a comment, sign in
-
Selected targetable biomarkers in solid tumours (from https://lnkd.in/g8pYkZwK) #biomarkers #cancer #oncology #cancerresearch #oncologyresearch #precisionmedicine #preventivemedicine
To view or add a comment, sign in
-
This is a #MustRead #Whitepaper if you want to understand where the research frontier in the #FightAgainstCancer lies. Learn what is in the R&D #pipeline for the new modalities as #ADCs, #bsAbs, and #RLTs. An excellent work by Markus Gores and Stefan Lutzmayer which I greatly appreciate for its uncompromising #quality and profound #insights. #oncology #research #pipeline
Oncology remains a powerhouse of innovation, with over 100 new cancer treatments expected to launch in the next five years. Download your copy of our latest white paper by authors Markus Gores and Stefan Lutzmayer for insights into novel therapeutic modalities and success factors for #oncology innovators. https://bit.ly/3ZgLLw8 #AnalyticsLink #IQVIAMIDAS #PharmaDeals
To view or add a comment, sign in
-
Antibody-drug conjugates (ADCs) are revolutionizing how we approach cancer treatment. Our in-depth presentation covers the entire ADC journey, highlighting their development, structure, and the complex bioanalytical methods required to bring these innovative therapies to market. With more than 100 ADC candidates in clinical trials, the future of targeted cancer therapy looks promising. #Oncology #ADCTherapy #BioanalyticalScience #Pharmacokinetics #WuXiAppTec https://hubs.li/Q02B-pBV0..
To view or add a comment, sign in
9,721 followers